Results 61 to 70 of about 71,439 (210)

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels

Case Reports in Oncology, 2013
Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer.
M. Czejka, A. Sahmanovic, P. Buchner, T. Steininger, C. Dittrich   +4 more
doaj   +1 more source

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. [PDF]

PLoS ONE, 2015
Expression of the tumor suppressor gene TUSC2 is reduced or absent in most lung cancers and is associated with worse overall survival. In this study, we restored TUSC2 gene expression in several wild type EGFR non-small cell lung cancer (NSCLC) cell ...
Bingbing Dai, Shaoyu Yan, Humberto Lara-Guerra, Hiroyuki Kawashima, Ryo Sakai, Gitanjali Jayachandran, Mourad Majidi, Reza Mehran, Jing Wang, B Nebiyou Bekele, Veerabhadran Baladandayuthapani, Suk-Young Yoo, Ying Wang, Jun Ying, Feng Meng, Lin Ji, Jack A Roth   +16 more
doaj   +1 more source

Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status

Frontiers in Oncology, 2022
Translational RelevanceEvaluation of targeted therapies is urgently needed for the majority of patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) who progress after immunochemotherapy.
Mercedes Porosnicu, Mercedes Porosnicu, Anderson O’Brien Cox, Joshua D. Waltonen, Paul M. Bunch, Ralph D’Agostino, Ralph D’Agostino, Thomas W. Lycan, Thomas W. Lycan, Richard Taylor, Dan W. Williams, Xiaofei Chen, Kirtikar Shukla, Brian E. Kouri, Tiffany Walker, Tiffany Walker, Gregory Kucera, Gregory Kucera, Hafiz S. Patwa, Hafiz S. Patwa, Christopher A. Sullivan, Christopher A. Sullivan, J. Dale Browne, J. Dale Browne, Cristina M. Furdui, Cristina M. Furdui   +25 more
doaj   +1 more source

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming. [PDF]

, 2016
The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor ...
Bagai, Rakesh, Bivona, Trever G, Danielpour, David, Feng, Yan, Leahy, Patrick, Lindner, Daniel, Ma, Patrick C, Rosell, Rafael, Shi, Ivy, Thiagarajan, Praveena S, Veigl, Martina, Wu, Xiaoliang, Yin, Lihong, Zhang, Wei, Zhang, Zhenfeng   +14 more
core   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Severe megaloblastic anemia in a patient with advanced lung adenocarcinoma during treatment with erlotinib: a case report and literature review

BMC Pulmonary Medicine
Background Erlotinib is a first-generation, tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) used for the treatment patients with NSCLC.
Xin Yan, Jingxian Kong, Jiacheng Wang, Caixia Wang, Hongchang Shen   +4 more
doaj   +1 more source

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]

, 2016
BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA, DE VITIS, CLAUDIA, Fabiana Fosca Ferrara, Francesca Bergantino, Francesca Fenizia, Gennaro Ciliberto, GIARNIERI, Enrico, GIOVAGNOLI, Maria Rosaria, Luigi Aurisicchio, MANCINI, RITA, MARIOTTA, Salvatore, Matilde Lambiase, Nicola Normanno, NOTO, ALESSIA, RICCI, Alberto, ROSCILLI, GIUSEPPE, Susan Costantini, TORRISI, Maria Rosaria   +17 more
core   +3 more sources

Mitochondrial reprogramming in lung cancer: a therapeutic vulnerability and a strategy for reversing drug resistance

The Journal of Pathology, Volume 269, Issue 2, Page 149-163, June 2026.
Abstract The conceptualization of mitochondria, previously restricted to their function as cellular ‘powerhouses’, has evolved to recognize their function as central coordinating hubs for the orchestration of cancer cell metabolism, signaling, and fate determination.
Woo Hyun Park
wiley   +1 more source

Protective Effects of Adenosine Triphosphate and Flunarizine on Erlotinib-Induced Ovarian Damage: An Experimental Study

Life
(1) Background: Erlotinib is a tyrosine kinase inhibitor (TKI) widely used in cancer therapy; however, its potential adverse effects on ovarian tissue have not been fully elucidated. The present study aimed to investigate erlotinib-induced ovarian injury
Arzu Yavuz, Kemine Uzel, Esra Tuba Sezgin, Mehmet Kuzucu, Nesrin Yılmaz, Gülcenaz Yazici, Engin Hendem, Halis Süleyman   +7 more
doaj   +1 more source